KaplanAP. Therapy of chronic urticaria: a simple, modern approach. Ann Allergy Asthma Immunol, 2014; 112(5):419–425.
4.
Sánchez-BorgesM, AseroR, AnsoteguiIJ, et al.WAO Scientific and Clinical Issues Council. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J, 2012; 5(11):125–147.
5.
GerickeJ, MetzM, OhanyanT, et al.Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol, 2017; 139:1059–1061.e1.
6.
IqbalK, BhargavaK, SkovPS, et al.A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria. Clin Transl Allergy, 2012; 2(1):19.
7.
BernsteinJA, LangDM, KhanDA, et al.The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol, 2014; 133:1270–1277.
8.
ZuberbierT, AbererW, AseroR, et al.The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy, 2014; 69(7):868–887.
9.
SimonsFE, SussmanGL, SimonsKJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol, 1995; 95(3):685–693.
10.
SainiS, RosenKE, HsiehHJ, et al.A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol, 2011; 128:567–573.e1.
11.
ErtasR, OzyurtK, OzluE, et al.Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol, 2017; 140(6):1749–1751.